THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER for THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 1st Quarter - Report | May 4, 2026 | $800,000 | Replaced |
| 1st Quarter - Amendment (this page) | May 8, 2026 | $80,000 | Yes |
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
All legislation related to Medicare site of service payment policy changes; the Cassidy Hassan Senate framework for hospital site neutral payments; Issues related to Medicare reimbursements for cancer services; Any legislation having to do with Medicare payments for dedicated cancer centers and hospitals, including satellite regulations; Medicare Advantage preauthorization; Medicare Advantage access issues; Cuts to services related to cancer diagnosis and treatment; Issues related to increased access to cancer detection. Issues related to "White Bagging" of pharmaceutical products; Policies related to the value of cancer care and initiatives that bend the cost curve; Issue related to site neutral payment reforms being included in the OBBB; Issues related to the FAIR Act and the work of the joint Taskforce developing a new method of cost reimbursement and federal grants.
| Lobbyist | Covered position, as disclosed |
|---|---|
| EDWARD MILLER | — |
Budget/Appropriations BUD
Issues related to the President's upcoming federal budget request; Funding levels for federal appropriation bills including Labor-HHS-Education, Homeland Security, Department of Defense, Commerce-Justice-Science that are related to biomedical research funding, healthcare delivery, training and education, protection of intellectual property and research. Funding for NIH and NCI. The impact of executive order on NIH indirect costs and what it means for the institution and the biomedical research space as a whole; the future of ARPA-H; federal grant recisions; Funding included in the CR packages that were passed.
| Lobbyist | Covered position, as disclosed |
|---|---|
| EDWARD MILLER | — |
Government Issues GOV
Issues related to the reorganization of HHS and its underlying agencies: NIH, CDC, CMS, and FDA; impact of executive order on NIH indirect costs and what it means for the institution and the biomedical research space as a whole; the future of ARPA-H; federal grant terminations; the future of global health programs;
| Lobbyist | Covered position, as disclosed |
|---|---|
| EDWARD MILLER | — |
Medical/Disease Research/Clinical Labs MED
Issues related to clinical trial design and patients obtaining drugs sooner in the course of the trial
| Lobbyist | Covered position, as disclosed |
|---|---|
| EDWARD MILLER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.